MedTrace Logo

THERApy De-escalation for TESTicular Cancer

NCT06309745 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-03-02

No results posted yet for this study

Summary

THERATEST is looking to collect data from 30 patients actively receiving de-escalation treatments or other standard of care treatments in two UK hospitals. THERATEST is a feasibility study to determine whether patients are willing to be recruited, the impact of de-escalation treatments on patients' cancers and quality of life, whether we should proceed with these treatments in a larger study, and if so how the study should be conducted. A feasibility study prepares the ground for a larger study and improves the chances of the subsequent study producing valuable evidence, and helps to avoid wasting precious resources on larger trials that are unlikely to be informative. We hope that information from THERATEST will bridge the current knowledge gap and allow clinicians to design bigger trials to actively compare the different treatment strategies.

Conditions

  • Seminoma

Interventions

PROCEDURE

retroperitoneal lymph node dissection

retroperitoneal lymph node dissection

DRUG

Carboplatin AUC10

Carboplatin AUC10

Sponsors & Collaborators

  • Queen Mary University of London

    lead OTHER

Principal Investigators

  • Prabhakar Rajan · Queen Mary University of London

Eligibility

Min Age
16 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-24
Primary Completion
2028-10-02
Completion
2028-10-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06309745 on ClinicalTrials.gov